Peter W. Reeh

TL;DR: It is concluded that the contribution of CB1-type receptors expressed on the peripheral terminals of nociceptors to cannabinoid-induced analgesia is paramount, which should enable the development of peripherally acting CB1 analgesic agonists without any central side effects.

TL;DR: It is found that concentrations of plasma methylglyoxal above 600 nM discriminate between diabetes-affected individuals with pain and those without pain, which provides a new basis for the design of therapeutic interventions for painful diabetic neuropathy.

TL;DR: This work shows that cooling excitable membranes progressively enhances the voltage-dependent slow inactivation of tetrodotoxin-sensitive VGSCs, and presents strong evidence for a specialized role of Nav1.8 in nociceptors as the critical molecule for the perception of cold pain and pain in the cold.

TL;DR: It is demonstrated that TREK‐1 qualifies as one of the molecular sensors involved in pain perception and as an attractive target for the development of new analgesics.

TL;DR: This work shows that LPS exerts fast, membrane delimited, excitatory actions via TRPA1, a transient receptor potential cation channel that is critical for transducing environmental irritant stimuli into nociceptor activity, and finds that pain and acute vascular reactions, including neurogenic inflammation (CGRP release) caused by LPS are primarily dependent onTRPA1 channel activation in nocICEptive sensory neurons, and develop independently of TLR4 activation.